Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07113106 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers

Study acronym: PANCOV
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 5, 2026 (before its estimated October 8, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruitingv3 Show 4 more changesShow less
    • Primary completion pushed from Jun 25, 2026 to Oct 8, 2026
    • Eligibility criteria shortened, about 14 words
    • Site details revised at 7 of 7 sites
    • Collaborators: 3 to 2
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The clinical trial is a phase1/2a, open-label, dose-escalating, multicentre trial evaluating the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster injection in adult participants in France. 48 participants divided into 4 cohorts will be included in the trial. Primary objectives are the following: * To determine the safety and reactogenicity of different doses (0.25 mg and 1 mg) of a booster of a CD40.Pan.CoV vaccine, adjuvanted or not, in healthy volunteers between Day 0 and Month1 * To determine the humoral immune response (neutralizing antibody titers) induced by different doses (0.25 mg and 1 mg) of a booster of a CD40.Pan.CoV vaccine, adjuvanted or not, at Month1 after administration
Trial Details
NCT Number NCT07113106
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France, Unité Mixte de Service 54 Methods and Applied Research for Trials (UMS 54 MART)
Conditions
(from sponsor)		 Healthy Volunteers
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov